Patents Assigned to AstraZeneca AB, a Swedish corporation
-
Publication number: 20040235006Abstract: This invention relates to polymorphisms in the human OATPC gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the OATPC gene, and to the use of OATPC polymorphism in treatment of diseases with OATPC transportable drugs such as statins.Type: ApplicationFiled: October 31, 2003Publication date: November 25, 2004Applicant: AstraZeneca AB, a Swedish corporationInventors: Monisola Adeokun, Helen Ambrose, Carl J. Cresswell, Adam J. Dudley
-
Publication number: 20040171550Abstract: A pharmaceutical composition including a mixture of active compounds (A) a pharmaceutically active polypeptide, and (B) an enhancer compound which enhances the systemic absorption of the polypeptide in the lower respiratory tract of a patient, the mixture being in the form of a dry powder for inhalation in which at least 50% of the total mass of the active compounds consists of primary particles having a diameter less than or equal to about 10 microns, the primary particles optionally being formed into agglomerates.Type: ApplicationFiled: March 3, 2004Publication date: September 2, 2004Applicant: AstraZeneca AB, a Swedish corporationInventors: Kjell Goran Erik Backstrom, Carl Magnus Olof Dahlback, Peter Edman, Ann Charlotte Birgit Johansson
-
Publication number: 20040137503Abstract: This invention relates to polymorphisms in the human P2X7 gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the P2X7 gene, and to the use of P2X7 polymorphism in treatment of diseases with P2X7 drugs.Type: ApplicationFiled: January 29, 2004Publication date: July 15, 2004Applicant: AstraZeneca AB, a Swedish CorporationInventor: John Edward Norris Morten
-
Publication number: 20040091912Abstract: This invention relates to novel sequence and polymorphisms in the human flt-1 gene. Eight specific polymorphisms are identified. The invention also relates to methods and materials for analysing allelic variation in the flt-1 gene and to the use of flt-1 polymorphism in the diagnosis and treatment of angiogenic diseases and cancer. Diseases associated with pathological angiogenesis include diabetic retinopathies, psoriasis, rheumatoid arthritis and endometriosis.Type: ApplicationFiled: July 16, 2003Publication date: May 13, 2004Applicant: AstraZeneca AB, a Swedish corporationInventor: John C. Smith
-
Publication number: 20040063676Abstract: The present invention relates to use of a composition for symptomatic relief, when needed, comprising, in admixtureType: ApplicationFiled: September 19, 2003Publication date: April 1, 2004Applicant: AstraZeneca AB, a Swedish corporationInventor: Tommy Ekstrom
-
Publication number: 20030223986Abstract: This invention relates to polymorphisms in the human pyruvate dehydrogenase complex E2 (PDH E2 or PDC E2) gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the PDH E2 gene, and to the use of PDH E2 polymorphism in the diagnosis and treatment of. diseases in which modulation of pyruvate dehydrogenase activity could be of therapeutic benefit, such as diabetes, asthma, obesity, sepsis and peripheral vascular disease. In particular, the invention is based on the discovery of two single nucleotide polymorphisms (SNPs) in the coding region of the human PDH E2 gene.Type: ApplicationFiled: March 27, 2003Publication date: December 4, 2003Applicant: AstraZeneca AB, a Swedish corporationInventors: John C. Smith, Rakesh Anand, John E.N. Morten
-
Publication number: 20030216541Abstract: A method of treating a patient in need of insulin treatment, including the steps of introducing into the lower respiratory tract of the patient an effective amount of a therapeutic preparation in the form of a dry powder containing (a) insulin and (b) an enhancer compound which enhances the absorption of insulin in the lungs of the patient.Type: ApplicationFiled: March 27, 2003Publication date: November 20, 2003Applicant: AstraZeneca AB, a Swedish corporationInventors: Kjell Goran Erik Backstrom, Carl Magnus Olof Dahlback, Peter Edman, Ann Charlotte Birgit Johansson
-
Publication number: 20030134886Abstract: The present invention relates to compounds of formula (I) 1Type: ApplicationFiled: November 6, 2002Publication date: July 17, 2003Applicant: ASTRAZENECA AB, a Swedish CorporationInventors: Kostas Karabelas, Matti Lepisto, Peter Sjo
-
Publication number: 20020037257Abstract: The invention provides finely divided, substantially crystalline particles of budesonide characterised in that they are substantially smooth and having a BET value from 1 to 4.5 m2/g, process for their preparation, a pharmaceutical composition comprising said particles, the use of said particles in the treatment of and in the manufacture of a medicament for use in the treatment of a respiratory disorder, and a method of treatment of respiratory disorders by administration, to a host in need of such treatment, said particles.Type: ApplicationFiled: November 6, 2001Publication date: March 28, 2002Applicant: AstraZeneca AB, a Swedish corporationInventors: Mikael Bisrat, Saeed Moshashaee